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| INTRODUC TI ON
Type 1 diabetes is a complex endocrine disease, which, in case of poor glycemic control, can lead to long-term microvascular complications, affecting kidneys, peripheral and central nervous system, and eyes. 1 The brain has also been recognized as a key organ that can be affected by long-standing type 1 diabetes. 2 Cross-sectional and longitudinal studies have shown that type 1 diabetes is associated with mild-to-moderate impairments in multiple neurocognitive domains compared with healthy controls.
3,4
The pathophysiology underlying these cognitive decrements in type 1 diabetes has not yet been fully elucidated. Risk factors for cognitive impairment include longer duration and early onset of diabetes as well as poor glycemic control, which suggests that hyperglycemia-induced damage is a pathophysiological determinant. 5, 6 Additionally, the presence of diabetic microangiopathy-that is, retinopathy, nephropathy, and neuropathy-was cross-sectionally associated with lower performance on several neuropsychological tests 3, 7, 8 and longitudinally with mild, but clinically relevant cognitive decline independent of lifetime HbA1c in the DCCT 1 and its epidemiological follow-up, the EDIC trial.
6
In type 1 diabetes, diabetic microangiopathy has been proposed to reflect a state of generalized microvascular dysfunction, including in the brain, which may lead to cSVD. On brain MRI, cSVD presents with ischemic WML, lacunar infarcts, and non-lobar cMB. 9, 10 The link between cSVD and peripheral microvascular complications is supported by data from our own group, which show higher prevalence of cMB in type 1 diabetes patients with proliferative retinopathy compared with those without. 11 In addition, diabetic retinopathy and neuropathy have been associated with the presence, volume, and severity of WML. 8, 12 We therefore hypothesize that generalized microvascular dysfunction, manifest by impaired microvascular function of the skin, and cSVD may correlate with decline in cognitive function over time.
In this prospective cohort study, we aimed to identify cerebral microangiopathy and skin capillary perfusion-as a surrogate marker of generalized microvascular function-as independent predictors of cognitive performance, controlling for possible confounding factors including HbA1c, diabetes duration, and the number of severe hypoglycemic events.
| MATERIAL S AND ME THODS
This prospective cohort study was part of a larger cross-sectional study conducted at the VU University Medical Centre, 13 
| Justification of sample size and group selection
This prospective cohort study is a randomly selected subsample of a larger cross-sectional study, in which type 1 diabetes patients with and without retinopathy and healthy controls were included. Due to funding limitations, we were able to include 50 of the 153 participants that were included at baseline. We chose to include two groups of 25 participants, instead of three groups of approximately 16 participants to increase the power of the study. The groups were selected based on the largest expected differences, taking into consideration that these results cannot be translated to type 1 diabetes patients in general.
| Cognitive functioning
All participants underwent a detailed neuropsychological assessment covering the domains of memory, information-processing speed, executive functions, attention, motor, and psychomotor speed. The tests were described previously. 15 General cognitive ability was constructed by averaging results with respect to the above-mentioned six domains. Raw scores were transformed into z-scores based on the mean and SD values from healthy controls of the larger cross-sectional study and inversed if necessary so that
cerebral microbleeds, cognitive performance, skin perfusion, type 1 diabetes, white matter lesions higher z-scores indicated better performance. To quantify change in cognitive performance over time, the RCI was computed from baseline and follow-up data by the following formula: ((Xfollow-upXbaseline)-(mean-controls follow-up-mean-controls baseline))/ standard deviation delta-score controls. Thus, for each test the mean delta-score of the controls was subtracted from the raw subject's delta-score and divided by the standard deviation of the delta-score of the controls. 16 To rule out confounding as a result of hypo-or hyperglycemia, glucose levels had to be between 4 and 15 mmol/L before and during neuropsychological testing. When outside of this range, patients were instructed to eat or inject insulin and testing was postponed for 30 min until blood glucose levels were within the required range. 
| Brain MRI
MRI scanning was performed on a 1.5-T magnetic resonance system (Siemens-Sonata, Erlangen, Germany). Further details on the magnetic resonance acquisition protocol have been described previously. 13 Vascular WML were assessed using T2 FLAIR and cerebral microbleeds using T2* susceptibility weighted imaging. All images were rated by an experienced neuroradiologist, who was blinded to any clinical information. Both WML and cMB were scored as present or not present. The Fazekas scale is often used to indicate severity of WML 18 ; however, in this study all but one subject had a Fazekas score of 1.
| Skin microvascular function
Peripheral microvascular function was assessed by skin capillary microscopy as described previously. 19 Briefly, nail fold capillaries in the dorsal skin of the third finger were visualized by a capillary microscope. Baseline capillary density (baseline) was defined as the number of continuously erythrocyte-perfused capillaries per square millimeter. Capillary density during peak reactive hyperemia (peak) was counted after 4 min of arterial occlusion. Maximal capillary density was assessed during VO. CR was calculated as the absolute and relative increase in capillary density from baseline to capillary density during peak reactive hyperemia. Table 1 shows the characteristics of type 1 diabetes patients and healthy controls at baseline. There was no difference from baseline to follow-up between type 1 diabetes patients and healthy controls 4.8 ± 0.9 mmol/L; P = 0.120). By definition, HbA1c was higher in type 1 diabetes patients (7.9 ± 1.0%) than in healthy controls (5.3 ± 0.3%; P < 0.001).
| Statistical analyses

| RE SULTS
| Participants
| Neurocognitive functioning
At baseline, type 1 diabetes patients had significantly lower general cognitive ability (z-score) relative to healthy controls (type These data are shown in Table 2 and were published previously 23 ). We have measured plasma glucose levels before neurocognitive testing. There were no significant differences between these measurements (baseline: 7.65 ± 3.75 versus follow-up: 8.29 ± 3.44; P = 0.559).
| White matter lesions and cerebral microbleeds
At baseline, the presence of WML (type 1 diabetes: 6 (24%); controls: 6 (24%); P = 0.999) and cMB (type 1 diabetes: 5 (20%); controls:
4 (17.4%); P = 0.941) was not significantly different between type 1 diabetes patients and healthy controls in (Table 3) .
| Skin microvascular function
At baseline, we did not detect significant differences between type 1 diabetes patients and healthy controls in skin capillary perfusion:
that is, baseline (type 1 diabetes 45.0 ± 7.7; controls: 50.6 ± 11.1; 
| Simple regression analysis
A simple regression analysis with general cognitive ability (the mean of all tests) as dependent variable and BMI, smoking, hypertension, HbA1c, diabetes duration, early onset of diabetes, and severe hypoglycemic events in the past (self-reported) as independent variables TA B L E 1 Baseline characteristics was performed to detect possible confounding factors. With a significance level of P < 0.100, HbA1c and the number of severe hypoglycemic events in the past were identified as possible confounding factors and were subsequently added to the multiple regression model (model 3).
| Multiple regression analysis
In type 1 diabetes patients, a significant association was detected between poorer general cognitive ability over time and presence of WML (ß = −0.419; P = 0.037), as well as with lower baseline capillary density (ß = 0.753; P < 0.001), peak hyperemia capillary density (ß = 0.743; P = 0.001), venous occlusion capillary density (ß = 0.675; P = 0.003), and absolute capillary recruitment (ß = 0.549; P = 0.022) at baseline (Figure 1 ). These associations were independent of age, sex (model 2), and HbA1c and severe hypoglycemic events (model 3) and were not present in the control population (Table   S4 ). There was no relationship between the presence of cMB and TA B L E 3 Baseline parameters of cerebral microangiopathy and capillary perfusion Data are presented as mean ± SD or number (percentage). CMB, cerebral microbleeds; CR, capillary recruitment (ie, increase of capillaries in n/mm² from baseline to peak perfusion); WML, white matter lesions. (Table S6 ). Next, we performed mediation analyses, with the change in general cognitive ability as outcome variable, skin perfusion parameters as independent variables, and WML as mediator, to assess whether WML (partly) mediated the effect of skin perfusion on the change in general cognitive ability. In type 1 diabetic patients, the total effect of skin perfusion (baseline: B = 0.030; 
| D ISCUSS I ON
In the present longitudinal study, we aimed to identify cerebral microangiopathy and skin capillary perfusion-as a surrogate marker for generalized microvascular function-as predictors of cognitive performance. We demonstrated that, in type 1 diabetes patients with proliferative retinopathy, the presence of WML and lower skin capillary perfusion at baseline was associated with lower performance in general cognitive ability over time, independent of age, sex, HbA1c, and severe hypoglycemic events. The association between WML and lower performance in general cognitive ability is driven by lower performance in motor speed, whereas lower capillary perfusion is related to lower performance in the attention domain. In contrast, in the healthy controls these associations were not found.
These data suggest a possible influence of WML and impaired microvascular function on cognitive performance in type 1 diabetes patients. In addition, we showed that the relationship between WML and lower cognitive performance was significantly reduced when and location with (subjective) cognitive failures in non-diabetic populations. 25, 26 Furthermore, in type 1 diabetes patients, higher WML volume was associated with lower information-processing speed. 12 It has been shown previously that patients with childhood-onset type 1 diabetes have more severe WML compared to healthy controls.
12
In our study, the presence of WML was similar in type 1 diabetes patients and healthy controls at baseline. This was unexpected, however consistent with a previous study with a larger sample size. 27 Study differences may be explained by variations in baseline characteristics such as age, diabetes duration, and the presence of earlyonset diabetes. Despite a similar prevalence in WML, we could only detect a relationship between the presence of WML at baseline and changes in general cognitive ability in the type 1 diabetes patients and not in the healthy controls. This suggests that WML do not have an effect on cognition in a healthy population with no other abnormalities and enough cognitive reserve capacity, whereas in a population with an underlying disease such as T1DM, WML may contribute to lower cognitive performance. Then again, when analyzing separate neurocognitive domains, the association between changes in motor speed and WML was found in both type 1 diabetes patients and healthy controls. The idea of a cognitive reserve capacity, which determines whether people experience cognitive decline or not has been postulated before. 28 In this study, we included middle-aged type 1 diabetes patients and control subjects, which we followed over a relatively short follow-up period. In this period, we did not detect a mean difference in general cognitive ability. We speculate that in older subjects we would most likely find more WML, more cMB as well as more pronounced microvascular dysfunction in both control subjects and type 1 diabetic patients, since aging itself is known to be an important contributor to both (skin) microvascular dysfunction 29 and cSVD. 28 This may lead to more pronounced effects of general cognitive ability, and perhaps more pronounced differences between healthy subjects and type 1 diabetic patients.
Diabetes is known to accelerate microvascular aging. In the present study, we were unable to detect significant differences in baseline skin microvascular function, yet baseline and peak hyperemia capillary density are lower in the type 1 diabetes patients, indicating a possible power problem. Indeed, a previous analysis performed by us in a larger sample showed a trend across groups toward lower baseline capillary function in patients with type 1 diabetes compared to controls (type 1 diabetes with retinopathy: 45 ± 7 capillaries/mm 2 ; type 1 diabetes patients without retinopathy: 46 ± 9 capillaries/mm 2 ; healthy controls: 48 ± 10 n/ mm 2 ; P = 0.05). Similar results were shown for capillary density after arterial occlusion (peak reactive hyperemia). 11 We therefore assume that the differences we detected in this study are real, but not reaching statistical significance due to our small sample size.
The treatment of type 1 diabetes is based on the balance between lowering HbA1c levels, without increasing (the risk of) hypoglycemic events. In our study, both HbA1c and severe hypoglycemic events were associated with cognitive performance over time, but neither influenced the relationship between WMLs and skin capillary perfusion with cognitive performance over time in the multiple regression model. The relationship between hypoglycemic episodes and cognitive dysfunction in middle-aged type 1 diabetes is less evident than the relationship between hyperglycemia-related damage on cognitive dysfunction. Retrospective studies in adult patients with type 1 diabetes have suggested an association between a history of recurrent severe hypoglycemia and a modest-to-severe degree of cognitive impairment. 41 However, large prospective studies have failed to confirm this association. 5, 41, 42 These contradictory results concerning the relationship between hypoglycemia and cognitive decline in middle-aged patients with type 1 diabetes may be partially explained by the positive relationship between the frequency of hypoglycemic episodes and glycemic control (lower HbA1c), of which the latter improves cognitive function.
In this study, lower skin microvascular function at baseline was associated with lower cognitive performance over time in type 1 diabetes patients. Furthermore, the association between the presence of WML and lower performance in general cognitive ability over time was significantly reduced to non-significant levels when adjusting for baseline capillary perfusion. Interestingly, we did not detect a correlation between skin microvascular function and cognition when analyzing our baseline data, even though the sample size of the cross-sectional study was larger. Using longitudinal data has the great advantage of being less hampered by inter-individual differences, which may have revealed these correlations. Nonetheless, we should be aware that, in this subsample, two data points have a large influence on the detected associations, despite the fact that they are not indicated as influential outliers by Cook's distance analyses. Theoretically, there is ground for a causal mechanism that links microvascular dysfunction to lower cognitive performance.
Maintenance of adequate cerebral perfusion is vital for the preservation of normal brain function, since the brain has no buffer for nutrients and oxygen and relies exclusively on perfusion to meet neuronal metabolic demand. 43 Cerebral autoregulation, including myogenic responses to changes in blood pressure, is an important mechanism for maintaining stable cerebral blood flow and to prevent hypoxia, hypo-and hypercapnia. [43] [44] [45] In addition to myogenic responses, cerebral perfusion also depends on microvascular endothelial function. Endothelium-dependent NO production is a key contributor of moment-to-moment adjustment of regional cerebral perfusion to changes in neuronal activity. 43 Lower peak hyperemia and lower capillary recruitment of the skin could translate to both loss of this myogenic cerebral autoregulation and endothelium-dependent microvascular function. Loss of these functions can potentially reduce oxygen delivery and alter neuronal activation and may therefore have detrimental effects on the brain. Indeed, in type 1 diabetes patient total gray matter cerebral blood flow is reduced 39, 46 and regional cerebral hemodynamic response to incremental exercise is blunted compared with control subjects. 47 Furthermore, in animal models of diabetes, improvement of cerebral blood flow by chronic treatment with an angiotensin-converting enzyme inhibitor (ACE-inhibitor) was found to be associated with improvement of cognitive function. 48 Limitations of our study design have to be considered, including the small sample size and observational character of the study. The small sample size made it impossible to correct for all possible confounding factors. In studies using MRI, this is often the case, since MRI techniques are expensive and time-consuming. We therefore chose several confounding factors based on current literature 20, 21 and performed a simple regression analysis to identify variables for the multiple regression model. Furthermore, this was an observational study, which makes it impossible to draw conclusions on causality. Nevertheless, the prospective correlations we found fit the hypothesis that generalized impairment of microvascular function is involved in cognitive performance over time in subjects with type 1 diabetes. Other limitations include the follow-up time, which was fairly brief (<4 years), and may explain why there were no significant changes in mean cognition in both groups. The use of a 1.5-T magnetic resonance system was standard during the initiation of the baseline study in 2006, yet stronger 3T systems more sensitively detect cMB with a lower inter-observer variability. To circumvent this problem as much as possible, we used susceptibility weighted imaging, which is highly sensitive to cMB. Nevertheless, our MRI field strength may have led to an underestimation of the amount of cMB and consequently a decreased chance of finding significant differences in cMB between the two study groups or correlations between cMBs and cognition over time. Third, in this study we selected T1DM patient with proliferative retinopathy, and therefore, the data cannot be translated to T1DM patients in general. It is likely that correlations will diminish when the two most influential data points are deleted from a relatively small dataset. Since these data points are not statistical outliers, and the data points in these correlations are not derived from two specific individuals, we consider it correct to keep these data points in our analysis. In addition, the association between general cognitive ability and peak capillary density (Figure 1 , panel C) remains statistically significant when deleting these two points (B = 0.533; P = 0.034).
In conclusion, this study demonstrates that in type 1 diabetes patients with proliferative retinopathy, the presence of WML and lower skin capillary perfusion at baseline is associated with lower performance in general cognitive ability over time. In addition, the relationship between WML and cognitive decline was significantly reduced when correcting for capillary perfusion measurements. We previously showed that type 1 diabetes patients with proliferative retinopathy have more cMB compared to those without retinopathy and that in patients with cMB capillary perfusion is impaired.
11
Together, these data fit our hypothesis that cSVD is a manifestation of generalized microvascular dysfunction, leading to cognitive dysfunction. Future research with a larger sample size and longer follow-up should confirm these observations. In addition, including type 1 diabetes patients without retinopathy helps to discriminate between hyperglycemia and microvascular damage as an underlying cause of lower cognitive performance.
| PER S PEC TIVE
These are the first prospective data that show a relationship between cognitive decline, cerebral small vessel disease, and microvascular dysfunction. These data fit our hypothesis that cerebral microangiopathy is a manifestation of generalized microvascular dysfunction, leading to cognitive dysfunction. Future research with a larger sample size and longer follow-up should confirm these observations. 
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